Schistosoma Mansoni
10
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Filling Key Research Gaps With Clinical Implications in Mansonellosis and Schistosomiasis: a Network Approach
Sm-p80 Schistosomiasis Challenge Study
Repeated Controlled Human Schistosoma Mansoni Infection
Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
Leiden University Medical Center Mini Donor Bank
Schistosoma Mansoni in Mwanza Region, Tanzania
A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni